Pfizer Inc. (NYSE:PFE) | Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE® (sirolimus) In Renal Transplant Recipients

[Business Wire] – Pfizer Inc. announced today top-line results from a Phase 3B/4 study of RAPAMUNE® evaluating kidney transplant patients who transitioned from tacrolimus-based therapy to RAPAMUNE® 3 to 5 months after transplant. . . . → Read More: Pfizer Inc. (NYSE:PFE) | Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE® (sirolimus) In Renal Transplant Recipients Similar posts: Company Update: Microsoft Corporation (NYSE:MSFT) – Microsoft announces plan to train veterans for tech jobs ConocoPhillips announces production startup, first oil from Ekofisk South – ConocoPhillips (NYSE:COP) China announces more stimulus